TheraRadar
← Back
Data updated: Jun 28, 2026

LUNDBECK PHARMS LLC

Specialty

LUNDBECK PHARMS LLC is a specialty pharmaceutical company focused on Neurology. Key products include ONFI.

2009
Since
3
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
2 Small Molecules

LUNDBECK PHARMS LLC's Key Drugs

LUNDBECK PHARMS LLC's core commercial portfolio centers on ONFI, spanning Neurology — its most strategically important drugs approved in the last 15 years.

LUNDBECK PHARMS LLC's Recent FDA Approvals

New NDA/BLA approvals for LUNDBECK PHARMS LLC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

LUNDBECK PHARMS LLC's Therapeutic Areas

LUNDBECK PHARMS LLC's approved drugs and pipeline span 1 therapeutic area, led by Neurology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Neurology 100%
2 drugs

LUNDBECK PHARMS LLC's Top Competitors

LUNDBECK PHARMS LLC's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

LUNDBECK PHARMS LLC Pipeline Snapshot

Active clinical trials for LUNDBECK PHARMS LLC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • ONFI leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Neurology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling